Harliku — Cigna

Initial criteria

• Diagnosis is supported by ONE of the following (i or ii): i. Genetic testing confirms biallelic pathogenic or likely pathogenic variants in the homogentisate 1,2 dioxygenase (HGD) gene; OR ii. Patient has elevated levels of homogentisic acid (HGA) in the urine; AND
• Medication is prescribed by or in consultation with a rheumatologist or metabolic disease specialist (or specialist who focuses in the treatment of metabolic diseases)

Approval duration

1 year